Evidence map›Paper›PMID 39182315›Full record

Trial reportVaccine2024

Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March - December 2021.

Nadja A Vielot, Nicole K Kelly, Christina Ludema, Molly Rosenberg, Elizabeth R Brown, Holly E Janes, James G Kublin, Kathryn E Stephenson, Jasmine R Marcelin, Audrey Pettifor

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04811664 (A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04811664 phase3completednot on this map

A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2021 to 2021Enrolled1,923ConditionsSARS-CoV-2 InfectionArmsModerna COVID-19 Vaccine
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nadja A VielotUniversity of North Carolina at Chapel Hill, Department of Family Medicine; Chapel Hill, NC, United States. Electronic address: nadjavielot@unc.edu.
Nicole K KellyUniversity of North Carolina at Chapel Hill, Department of Epidemiology; Chapel Hill, NC, United States.
Christina LudemaIndiana University Bloomington, Department of Epidemiology and Biostatistics; Bloomington, IN, United States.
Molly RosenbergIndiana University Bloomington, Department of Epidemiology and Biostatistics; Bloomington, IN, United States.
Elizabeth R BrownVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, United States.
Holly E JanesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, United States.
James G KublinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, United States.
Kathryn E StephensonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, United States; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States.
Jasmine R MarcelinDivision of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, United States.
Audrey PettiforUniversity of North Carolina at Chapel Hill, Department of Epidemiology; Chapel Hill, NC, United States.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Training in Infectious Disease Epidemiology (TIDE)T32AI070114 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian W Pence · 2007 to 2026
$4.0M
NIAID NIH HHS T32 AI070114NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

backgroundThe introduction of vaccines during the COVID-19 pandemic provided an opportunity to slow transmission of SARS-CoV-2, but initial uptake of COVID-19 vaccination was slow. We analyzed data from a randomized clinical trial of the mRNA-1273 vaccine (NCT04811664) to describe the patterns of uptake of COVID-19 vaccines among young adults.

methodsThe CoVPN 3006 trial randomized adults ages 18-29 from 44 sites in the United States to receive 1) immediate mRNA-1273 vaccination from the study site, or 2) standard of care, including the option to seek vaccination at any time in the future. Randomization occurred between March and November 2021, and an observational arm of adults who declined vaccination was enrolled beginning June 2021. Among participants in the standard of care (SoC) or Vaccine Declined arms, we estimated demographic, behavioral, and health history correlates of vaccination, and the four-month cumulative incidence of COVID-19 vaccination using inverse probability weighted Kaplan-Meier estimators.

resultsAmong 728 SoC and 470 Vaccine Declined participants, 79% and 16% received COVID-19 vaccination, respectively. SoC and Vaccine Declined participants were more likely to seek and receive vaccination if they reported COVID-19 preventive behaviors, including wearing masks, physically distancing, and avoiding large gatherings. We identified strong predictors of vaccination in the Vaccine Declined arm, including attending class in person (adjusted risk ratio [aRR]: 0.47, 95% confidence interval [CI] 0.21, 1.03), having a COVID-19 relevant medical condition (aRR: 1.95, 95% CI: 0.89, 4.26), and avoiding large gatherings (aRR: 2.24, 95% CI: 1.18, 4.25), though low vaccination rates in this arm led to imprecise estimates.

conclusionsIndividuals who initially decline vaccination can be convinced to vaccinate, particularly if they are already practicing other forms of COVID-19 prevention. Continued outreach and education from the scientific community can combat low vaccine confidence.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2Vaccination2019-nCoV Vaccine mRNA-1273AdolescentAdultFemaleHumansMaleUnited StatesYoung Adult2019-nCoV Vaccine mRNA-1273COVID-19 VaccinesAdultsCOVID-19Randomized controlled trialSARS-CoV-2Vaccination

Identifiers

PMID39182315
PMCPMC11413740

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.